Paclitaxel trevatide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Paclitaxel trevatide
Accession Number
DB06171
Type
Biotech
Groups
Investigational
Description

Three paclitaxel molecules linked by a cleavable succinyl ester linkage to a brain peptide vector, Angiopep-2, conjugate named ANG1005.

Synonyms
Not Available
External IDs
ANG-1005 / ANG1005
Categories
UNII
8P77G99D3P
CAS number
1075214-55-9

Pharmacology

Indication

Investigated for use/treatment in brain cancer.

Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Paclitaxel trevatide.
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Paclitaxel trevatide.
AldoxorubicinThe risk or severity of cardiotoxicity can be increased when Aldoxorubicin is combined with Paclitaxel trevatide.
AmsacrineThe risk or severity of cardiotoxicity can be increased when Amsacrine is combined with Paclitaxel trevatide.
AnastrozoleThe risk or severity of cardiotoxicity can be increased when Anastrozole is combined with Paclitaxel trevatide.
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Paclitaxel trevatide.
Arsenic trioxideThe risk or severity of cardiotoxicity can be increased when Arsenic trioxide is combined with Paclitaxel trevatide.
BevacizumabThe risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Paclitaxel trevatide.
BleomycinThe risk or severity of cardiotoxicity can be increased when Bleomycin is combined with Paclitaxel trevatide.
BortezomibThe risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Paclitaxel trevatide.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableAdvanced Solid Tumors With and Without Brain Metastases1
1CompletedNot AvailableRecurrent or Progressive Malignant Glioma1
2CompletedTreatmentCancer, Breast / Metastatic Brain Tumors2
2CompletedTreatmentGlioblastomas / Gliomas / Recurrent Brain Tumors1
2TerminatedTreatmentNon-small Cell Lung Cancer (NSCLC) With Brain Metastases1
3Not Yet RecruitingTreatmentHER2-Negative Breast Cancer / Leptomeningeal Carcinomatosis / Leptomeningeal Metastases / Metastatic Brain Tumors1
Not AvailableNo Longer AvailableNot AvailableAnaplastic Astrocytoma (AA) / Anaplastic Oligodendroglioma (AO) / Breast Cancer With Recurrent Brain Metastases / Leptomeningeal Carcinomatosis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on March 19, 2008 10:15 / Updated on June 04, 2019 06:21